Morningside Group

Morningside Group was founded in 1986, by the Chan family of Hong Kong, to make private equity and venture capital investments. The group is managed by investment professionals who are entrepreneurial, have deep industry knowledge and are effective in the local environment in which they operate. In addition to its investment activities, Morningside Group is strongly committed to social responsibility.

TypeInvestor
HQShanghai, CN
Founded1986
Websitemorningside.com
Cybersecurity ratingCMore
Morningside Group was founded in 1986 and is headquartered in Shanghai, CN

Viewing summary data as a guest

Sign up for free to see all data

Morningside Group Office Locations

Morningside Group has an office in Shanghai
Show all (1)

Morningside Group Online and Social Media Presence

Embed Graph

Morningside Group Blogs

Apnimed Strengthens its Scientific Advisory Board with Experts in Sleep Disorders

Businesswire CAMBRIDGE, Mass. Apnimed, a clinical-stage pharmaceutical company focused on advancing medicines to treat sleep apnea and related disorders, today announced its Scientific Advisory Board (SAB). The SAB will help guide the advancement of the company’s pipeline of small molecule solutions…

Atea Pharmaceuticals Strengthens Management Team with Appointment of Clinical and Regulatory Leadership

Contify Life Science News Atea Pharmaceuticals, Inc. issued the following news release: - Executive Vice President of Clinical Sciences and Vice President of Regulatory Bring Decades of Clinical and Regulatory Experience Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discover…

F2G Closes US$60.8 Million Financing to Fund Late Stage Development of Novel Mechanism Antifungal Agent

PR Newswire Europe Financing round led by Cowen Healthcare Investments with strong support from existing investors Novo Holdings, Morningside Ventures, Brace Pharma Capital and Advent Life Sciences F2G Ltd, a UK- and Austria-based biotech developing novel therapies for life-threatening systemic fung…

Vigeo’s Tumor Microenvironment Platform Expands Indications and Combo Therapy Possibilities

Gail Dutton BioSpace Vigeo Therapeutics is expanding indications for its tumor microenvironment (TME)-targeting oncology platform, which inhibits tumor growth by reprogramming normal cells that were recruited and coopted by a tumor. Dose expansion for its Phase Ib/II study is ongoing for multiple so…

Amylyx Pharmaceuticals Announces New England Journal of Medicine Publication of Pivotal AMX0035 Data Demonstrating Statistically Significant Benefit in People with ALS

- Patients Retained Function Longer on AMX0035 Versus Placebo; Study Achieved Its Primary Outcome of a Difference on the Revised ALS Functional Rating Scale - AMX0035 is the First Investigational Therapy to Demonstrate Statistically Significant Benefit on this Prespecified Primary Outcome in People …

UMass Medical School Announces ALS Breakthrough

Grant Welker, Worcester Business Journal July 8, 2020 Researchers at UMass Medical School and Massachusetts General Hospital have announced a major breakthrough in ALS research: a therapy that suppresses a harmful gene that causes the nervous system disease. The advancement, announced by researchers…
Show more

Morningside Group Frequently Asked Questions

  • When was Morningside Group founded?

    Morningside Group was founded in 1986.

  • Where are Morningside Group offices?

    Morningside Group has an office in Shanghai.

  • How many offices does Morningside Group have?

    Morningside Group has 1 office.